INTRODUCTION: The unified medical prescription was implemented as a policy to decrease the overall health expenditures and increase the use of generic drugs. The main objective of this study was to evaluate the perception of Lebanese physicians towards the unified medical Prescription and its impact on the overall generic prescription. Additionally, an overview was assessed concerning the type of drugs that physicians tend more to accept to be substituted to generic alternatives.
METHODS: A cross-sectional descriptive study was conducted in Lebanon over a period of three months targeting physicians in their private clinics or in various hospitals using a survey as an instrument.
RESULTS: Our findings demonstrated that more than the half of respondents (56.6%) believed that the unified medical prescription preserves the exclusivity for physicians to choose the medication while only 39.5% of physicians think that the unified medical prescription encouraged generic prescription and almost 42% admitted that the unified medical prescription lowers the medical cost for the patient.
DISCUSSION: Despite that this new medical form of prescription is a high achievement for the Lebanese Ministry Of Public Health, this last should make essential actions: coordinating the generic drug substitution policy and monitoring its implementation over time and achievement of goals; establishing appropriate pricing system and medicines prices and controlling the interactions between physicians, pharmacists, and pharmaceutical industries; ensure their full commitment; and update the national list of substitutable generic drugs.
CONCLUSION: The main objective of the unified medical prescription is to decrease the pharmaceutical expenditure and to provide access to medications for patients with lower socio-economic status. Lebanese physicians reported that this tool did not achieve its goal yet but have an impact on lowering the medical cost for patients and promoting generic prescription.
PiabuoSMTieguhongJC. Health expenditure and economic growth (2017) - a review of the literature and analysis between the economic community for central African States (CEMANC) and selected African countries. Health Econ Rev2017; 27: 1–13.
HogerzeilHVMirzaZ. The world medicines situation 2011: access to essential medicines as part of the right to health. Geneva: World Health Organization, 2011.
4.
DimassiHMarounABSaadehM, et al.Views of community pharmacists in Lebanon on the unified prescription: a mixed method study. East Mediterr Health J2020; 26(12): 1539–1547.
5.
DimassiHMarounABSaadehM, et al.Views of community pharmacists in Lebanon on the unified prescription: a mixed method study. East Mediterr Health J2020; 26(12): 1539–1547.
6.
Organization for Economic Cooperation and Development (OECD). Health at a glance: OECD indicators. Paris, France: OECD publishing, 2013.
7.
El-JardaliFFadlallahRMorsiRZ, et al.Pharmacists’ views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study. Implement Sci2017; 12(1): 23
8.
DunneSShannonBDunneC, et al.A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol2013; 14(1): 1–19.
9.
CameronAMantel-TeeuwisseAKLeufkensHGM, et al.Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?Value Health2012; 15(5): 664–673.
10.
Blominvest Bank. Pharmaceuticals and healthcare in Lebanon: numerous opportunities to explore. Beirut, Lebanon: Blominvest Bank, 2016.
KeeKWCharCWTYipAYF. A review on interventions to reduce medication discrepancies or errors in primary or ambulatory care setting during care transition from hospital to primary care. J Family Med Prim Care2018; 7(3): 501.
GodmanBWettermarkBHoffmannM, et al.Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res2009; 9(1): 65–83.
15.
SermetCAndrieuVGodmanB, et al.going pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Pol2010; 8(1): 7–24.
16.
MurshidMAMohaidinZ. Physicians’ perceptions towards brand medicine and its effect on prescribing: a narrative review. J Generic Med2017; 13(4): 153–183. DOI: 10.1177/1741134317709509.
17.
ColganSFaasseKMartinLR, et al.Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open2015; 5(12): e008915.
18.
AwaisuAKheirNIbrahimMIM, et al.Knowledge, attitudes, and practices of community pharmacists on generic medicines in Qatar. Int J Clin Pharm2014; 36(2): 394–404.
19.
El-DahiyatFKayyaliRBidgoodP. Physicians’ perception of generic and electronic prescribing: a descriptive study from Jordan. J Pharm Pol Pract2014; 7(1): 7, DOI: 10.1186/2052-3211-7-7.
20.
AmeriMAMohamedWMakramallaE, et al.Renal patients’ views on generic prescribing and substitution: example from the United Arab Emirates. East Mediterr Health J2013; 19(4): 373–381, DOI: 10.26719/2013.19.4.373.
21.
KalischLMRougheadEEGilbertAL. Pharmaceutical brand substitution in Australia—are there multiple switches per prescription?Aust N Z J Public Health2007; 31(4): 348–352.
22.
MottDAClineRR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care2002; 40(8): 662–674.
23.
O’LearyAUsherCLynchM, et al.Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland. BMC Res Notes2015; 8: 790.
24.
EssSMSchneeweissSSzucsTD. European healthcare policies for controlling drug expenditure. Pharmacoecon2003; 21(2): 89–103.
25.
AllavenaCJacometCPereiraB, et al.Acceptability and confidence in antiretroviral generics of physicians and HIV-infected patients in France. J Int AIDS Soc2014; 17(Suppl 3): 19608.
26.
Simmenroth-NaydaAHummers-PradierELedigT, et al.[Prescription of generic drugs in general practice. Results of a survey of general practitioners]. Generikaverordnung Durch Hausärzte Med Klin2006; 101: 705–710, (Nr. 9).
27.
CharanJSaxenaDChaudhriM, et al.Opinion of primary care physicians regarding prescription of generic drugs: A Cross-sectional study. J Fam Med Prim Care2021; 10: 1390–1398.
28.
PrasadMChakrabortyADeepN. Knowledge, attitude, and practice of generic drugs among doctors in a tertiary care hospital. Innovare J Med Sci2019; 7: 1–3.
29.
ČatićTAvdagićLMartinovićI. Knowledge and attitudes of physicians and pharmacists towards the use of generic medicines in Bosnia and Herzegovina. Med Glas Off Publ Med Assoc Zenica-doboj Cant Bosnia Herzeg2017; 14: 25–32.
30.
NguyenTAKnightRRougheadEE, et al.Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plan2015; 30(2): 267–280.
31.
KaplanWARitzLSVitelloM, et al.Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy2000–2010; 106(3): 211–224.
32.
HassaliMAAlrasheedyAAMcLachlanA, et al.The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J2014; 22(6): 491–503.
33.
AlkhuzaeeFSAlmalkiHMAttarAY, et al.Evaluating community pharmacists’ perspectives and practices concerning generic medicines substitution in Saudi Arabia: a cross-sectional study. Health Policy2016; 120(12): 1412–1419.
34.
SkipperNVejlinR. Determinants of generic vs. brand drug choice: evidence from population-wide Danish data. Soc Sci Med2015; 130: 204–215, DOI: 10.1016/j.socscimed.2015.01.013.
35.
PalagyiMLassanovaM. Patients attitudes towards experience with use of generics in Slovakia, performance of generic substitution. Bratisl Lek Listy2008; 109(7): 324–328.
36.
ChongCPHassaliMABahariMB, et al.Evaluating community pharmacists’ perceptions of future generic substitution policy implementation: a national survey from Malaysia. Health Policy2010; 94(1): 68–75.
37.
AndersenSE. Implementation of a new prescription system. A qualitative survey of organizational barriers. Ugeskr Laeger2002; 164(38): 4449–4453, DOI: 10.1136/qhc.11.1.19.
38.
RubakSAndersenM-LEMainzJ, et al.How do general practitioners, pharmacists and patients evaluate the substitution system for prescription in Denmark?Eur J Gen Pract2002; 8(1): 13–17, DOI: 10.3109/13814780209160823.
39.
MeredithP. Bioequivalence and other unresolved issues in generic substitution. ClinTher2003; 25: 2875–2890.
40.
SandersonJHLewisJA. Difference in side effect incidence in patients on proprietary and generic propranolol. Lancet1986; 327: 967–968.
DigheSV. A review of the safety of generic drugs. Transpl Proc1999; 31(Suppl 3A): 23S–24S.
43.
MeredithPA. Generic drugs. Therapeutic equivalence. Drug Saf1996; 15: 233–242.
44.
SchaeferKHansenAOMaerkedahlH, et al.Changing GPs' prescription patterns through guidelines and feedback. Intervention study. Intervent Study Pharmacoepidemiol Drug Saf2007; 16(6): 695–704.
45.
Al-TamimiSKHassaliMAShafieAA, et al.The need to incorporate generic medicines topic in the curriculum of Yemeni pharmacy colleges. Int J Pharm Pract2016; 24(1): 72–73.
46.
AlrasheedyAAHassaliMAAljadheyH, et al. The need to cover generic medications and generic substitution practice in the curricula of pharmacy colleges in Saudi Arabia. Am J Pharm Educ2014; 78(5): 108.
